O	0	10	Comparison
O	11	13	of
O	14	21	rapidly
O	22	28	cycled
O	29	35	tandem
B-intervention	36	40	high
I-intervention	40	41	-
I-intervention	41	45	dose
I-intervention	46	58	chemotherapy
I-intervention	59	63	plus
I-intervention	64	74	peripheral
I-intervention	74	75	-
I-intervention	75	80	blood
I-intervention	81	85	stem
I-intervention	85	86	-
I-intervention	86	90	cell
I-intervention	91	98	support
O	99	105	versus
B-control	106	110	dose
I-control	110	111	-
I-control	111	116	dense
I-control	117	129	conventional
I-control	130	142	chemotherapy
O	143	146	for
O	147	155	adjuvant
O	156	165	treatment
O	166	168	of
O	169	173	high
O	173	174	-
O	174	178	risk
O	179	185	breast
O	186	192	cancer
O	192	193	:
O	194	201	results
O	202	204	of
O	205	206	a
O	207	218	multicentre
O	219	224	phase
O	225	228	III
O	229	234	trial
O	234	235	.

O	236	242	Breast
O	243	249	cancer
O	250	254	with
O	255	264	extensive
O	265	273	axillary
O	273	274	-
O	274	279	lymph
O	279	280	-
O	280	284	node
O	285	296	involvement
O	297	300	has
O	301	302	a
O	303	307	poor
O	308	317	prognosis
O	318	323	after
O	324	336	conventional
O	337	346	treatment
O	346	347	.

O	348	350	In
O	351	357	trials
O	358	362	with
O	363	373	historical
O	374	382	controls
O	382	383	,
O	384	388	high
O	388	389	-
O	389	393	dose
O	394	406	chemotherapy
O	407	415	produced
O	416	424	improved
O	425	433	outcomes
O	433	434	.

O	435	437	We
O	438	446	compared
O	447	449	an
O	450	459	intensive
O	460	466	double
O	466	467	-
O	467	472	cycle
O	473	477	high
O	477	478	-
O	478	482	dose
O	483	495	chemotherapy
O	496	503	regimen
O	504	508	with
O	509	511	an
O	512	523	accelerated
O	524	538	conventionally
O	539	544	dosed
O	545	552	regimen
O	553	555	in
O	556	560	high
O	560	561	-
O	561	565	risk
O	566	572	breast
O	573	579	cancer
O	580	582	in
O	583	584	a
O	585	596	multicentre
O	597	602	trial
O	602	603	.

B-eligibility	604	612	Patients
I-eligibility	613	617	with
I-eligibility	618	620	at
I-eligibility	621	626	least
I-eligibility	627	631	nine
I-eligibility	632	640	positive
I-eligibility	641	646	nodes
O	647	651	were
O	652	660	randomly
O	661	669	assigned
O	670	676	either
O	677	680	two
O	681	688	courses
O	689	691	of
O	692	703	accelerated
O	704	705	(
O	705	706	2
O	706	707	-
O	707	711	week
O	712	721	intervals
O	721	722	,
O	723	727	with
O	728	738	filgrastim
O	739	746	support
O	746	747	)
O	747	748	,
O	749	763	conventionally
O	764	769	dosed
O	770	780	epirubicin
O	781	784	and
O	785	801	cyclophosphamide
O	802	810	followed
O	811	813	by
O	814	817	two
O	818	825	courses
O	826	828	of
O	829	833	high
O	833	834	-
O	834	838	dose
O	839	851	chemotherapy
O	852	853	(
O	853	863	epirubicin
O	863	864	,
O	865	881	cyclophosphamide
O	881	882	,
O	883	886	and
O	887	895	thiotepa
O	896	905	supported
O	906	908	by
O	909	919	peripheral
O	919	920	-
O	920	925	blood
O	926	937	progenitors
O	937	938	)
O	939	941	or
O	942	946	four
O	947	956	identical
O	957	963	cycles
O	964	966	of
O	967	977	epirubicin
O	978	981	and
O	982	998	cyclophosphamide
O	999	1007	followed
O	1008	1010	by
O	1011	1016	three
O	1017	1023	cycles
O	1024	1026	of
O	1027	1038	accelerated
O	1039	1055	cyclophosphamide
O	1055	1056	,
O	1057	1069	methotrexate
O	1069	1070	,
O	1071	1074	and
O	1075	1087	fluorouracil
O	1087	1088	.

O	1089	1092	The
O	1093	1100	primary
O	1101	1109	endpoint
O	1110	1113	was
B-outcome-Measure	1114	1119	event
I-outcome-Measure	1119	1120	-
I-outcome-Measure	1120	1124	free
I-outcome-Measure	1125	1133	survival
O	1133	1134	.

O	1135	1143	Analyses
O	1144	1148	were
O	1149	1153	done
O	1154	1158	both
O	1159	1161	by
O	1162	1171	intention
O	1172	1174	to
O	1175	1180	treat
O	1181	1184	and
O	1185	1188	per
O	1189	1197	protocol
O	1197	1198	.

B-total-participants	1199	1202	403
O	1203	1211	patients
O	1212	1216	were
O	1217	1225	enrolled
O	1225	1226	;
B-intervention-participants	1227	1230	201
O	1231	1235	were
O	1236	1244	assigned
O	1245	1249	high
O	1249	1250	-
O	1250	1254	dose
O	1255	1267	chemotherapy
O	1268	1271	and
B-control-participants	1272	1275	202
O	1276	1288	conventional
O	1289	1298	treatment
O	1298	1299	.

O	1300	1303	The
O	1304	1308	mean
O	1309	1315	number
O	1316	1318	of
O	1319	1327	positive
O	1328	1333	nodes
O	1334	1337	was
O	1338	1340	17
O	1340	1341	.
O	1341	1342	6
O	1342	1343	,
O	1344	1347	and
O	1348	1354	median
O	1355	1361	follow
O	1361	1362	-
O	1362	1364	up
O	1365	1368	was
O	1369	1371	48
O	1371	1372	.
O	1372	1373	6
O	1374	1380	months
O	1380	1381	.

B-outcome	1382	1383	4
I-outcome	1383	1384	-
I-outcome	1384	1388	year
I-outcome	1389	1394	event
I-outcome	1394	1395	-
I-outcome	1395	1399	free
I-outcome	1400	1408	survival
O	1409	1410	(
O	1410	1419	intention
O	1419	1420	-
O	1420	1422	to
O	1422	1423	-
O	1423	1428	treat
O	1429	1437	analysis
O	1437	1438	)
O	1439	1442	was
B-iv-bin-percent	1443	1445	60
I-iv-bin-percent	1445	1446	%
O	1447	1448	(
O	1448	1450	95
O	1450	1451	%
O	1452	1454	CI
O	1455	1457	53
O	1457	1458	-
O	1458	1460	67
O	1460	1461	)
O	1462	1464	in
O	1465	1468	the
O	1469	1473	high
O	1473	1474	-
O	1474	1478	dose
O	1479	1491	chemotherapy
O	1492	1497	group
O	1498	1501	and
B-cv-bin-percent	1502	1504	44
I-cv-bin-percent	1504	1505	%
O	1506	1507	(
O	1507	1509	37
O	1509	1510	-
O	1510	1512	52
O	1512	1513	)
O	1514	1516	in
O	1517	1520	the
O	1521	1528	control
O	1529	1534	group
O	1535	1536	(
O	1536	1537	p
O	1537	1538	=
O	1538	1539	0
O	1539	1540	.
O	1540	1545	00069
O	1545	1546	)
O	1546	1547	.

O	1548	1551	The
O	1552	1565	corresponding
B-outcome	1566	1573	overall
I-outcome	1574	1582	survival
O	1583	1586	was
B-iv-bin-percent	1587	1589	75
I-iv-bin-percent	1589	1590	%
O	1591	1592	(
O	1592	1594	69
O	1594	1595	-
O	1595	1597	82
O	1597	1598	)
O	1599	1605	versus
B-cv-bin-percent	1606	1608	70
I-cv-bin-percent	1608	1609	%
O	1610	1611	(
O	1611	1613	64
O	1613	1614	-
O	1614	1616	77
O	1616	1617	;
O	1618	1619	p
O	1619	1620	=
O	1620	1621	0
O	1621	1622	.
O	1622	1624	02
O	1624	1625	)
O	1625	1626	.

O	1627	1632	There
O	1633	1637	were
B-outcome	1638	1640	no
I-outcome	1641	1650	treatment
I-outcome	1650	1651	-
I-outcome	1651	1658	related
I-outcome	1659	1665	deaths
O	1665	1666	.

O	1667	1670	Our
O	1671	1678	finding
O	1679	1681	of
O	1682	1693	significant
O	1694	1706	improvements
O	1707	1709	in
O	1710	1714	both
O	1715	1720	event
O	1720	1721	-
O	1721	1725	free
O	1726	1729	and
O	1730	1737	overall
O	1738	1746	survival
O	1747	1750	for
O	1751	1755	high
O	1755	1756	-
O	1756	1760	dose
O	1761	1773	chemotherapy
O	1774	1782	compared
O	1783	1787	with
O	1788	1789	a
O	1790	1794	dose
O	1794	1795	-
O	1795	1800	dense
O	1801	1813	conventional
O	1814	1821	regimen
O	1822	1831	contrasts
O	1832	1836	with
O	1837	1840	the
O	1841	1848	results
O	1849	1851	of
O	1852	1857	other
O	1858	1865	studies
O	1865	1866	.

O	1867	1870	The
O	1871	1882	discrepancy
O	1883	1888	might
O	1889	1891	be
O	1892	1895	due
O	1896	1902	partly
O	1903	1905	to
O	1906	1912	design
O	1913	1924	differences
O	1925	1926	(
O	1926	1932	tandem
O	1932	1933	,
O	1934	1939	brief
O	1940	1949	induction
O	1949	1950	)
O	1951	1958	between
O	1959	1962	our
O	1963	1970	regimen
O	1971	1974	and
O	1975	1980	those
O	1981	1988	studied
O	1989	1991	in
O	1992	1997	other
O	1998	2004	trials
O	2004	2005	.

O	2006	2010	This
O	2011	2019	approach
O	2020	2026	merits
O	2027	2034	further
O	2035	2040	study
O	2040	2041	.
